Andrzej Orzeszko

Andrzej Orzeszko

Auto-generated profile, based on publicly available information

Andrzej Orzeszko

Agricultural University, Institute of Chemistry, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2008 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
MPMario Pagano
Mario Pagano
JBJenny Bain
Jenny Bain
ZKZygmunt Kazimierczuk
Zygmunt Kazimierczuk
SSStefania Sarno
Stefania Sarno
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
LPLuigi Pinna
Luigi Pinna
CK2 (casein kinase 2) is a very pleiotropic serine/threonine protein kinase whose abnormally high constitutive activity has often been correlated to pathological conditions with special reference to neoplasia. The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers. In the present study we show, by using a panel of approx. 80 protein kinases, that DMAT and its parent compound TBI (or TBBz; 4,5,6,7-tetrabromo-1H-benzimidazole) are potent inhibitors of several other kinases, with special reference to PIM (provirus integration site for Moloney murine leukaemia virus)1, PIM2, PIM3, PKD1 (protein kinase D1), HIPK2 (homeodomain-interacting protein kinase 2) and DYRK1a (dual-specificity tyrosine-phosphorylated and -regulated kinase 1a). In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. In an attempt to improve selectivity towards CK2 a library of 68 TBB/TBI-related compounds have been tested for their ability to discriminate between CK2, PIM1, HIPK2 and DYRK1a, ending up with seven compounds whose efficacy toward CK2 is markedly higher than that toward the second most inhibited kinase. Two of these, K64 (3,4,5,6,7-pentabromo-1H-indazole) and K66 (1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole), display an overall selectivity much higher than TBB and DMAT when tested on a panel of 80 kinases and display similar efficacy as inducers of apoptosis.

1 July 2007 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JBJan Balzarini
Jan Balzarini
BOBarbara Orzeszko
Barbara Orzeszko
JMJan Krzysztof Maurin
Jan Krzysztof Maurin
AOAndrzej Orzeszko
Andrzej Orzeszko

1 June 2011 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SSS. Sarno
S. Sarno
EPE. Papinutto
E. Papinutto
CFC. Franchin
C. Franchin
JBJ. Bain
J. Bain
MEM. Elliott
M. Elliott
LPLuigi Pinna
Luigi Pinna
CK2 denotes a pleiotropic, constitutively active protein kinase whose abnormally high level in many cancer cells is held as an example of “non oncogene addiction”. A wide spectrum of cell permeable, fairly specific ATP sitedirected CK2 inhibitors are currently available which are proving useful to dissect its biological functions and which share the property of inducing apoptosis of cancer cells with no comparable effect on their “normal” counterparts. One of these, CX-4945, has recently entered clinical trials for the treatment of advanced solid tumors, Castelmans disease and multiple myeloma. The solution of a wide range of 3D structures of inhibitors bound to the catalytic subunits of CK2 reveals that their efficacy substantially relies on hydrophobic interactions within a cavity which is smaller than in other protein kinases. Accordingly the potency of tetra-halogenated benzimidazoles increases upon replacement of chlorine by bromine and, even more, by iodine, and decreases if two unique bulky side chains on CK2 (Val66 and Ile174) are mutated to alanines. Many CK2 inhibitors have been tested on a panel of more than 60 kinases providing Promiscuity Scores useful to evaluate their selectivity, the lowest value (9.47), denoting highest selectivity, being displayed by quinalizarin. The observation that CK2 inhibitors with medium/high promiscuity scores share the ability to inhibit a group of protein kinases as effectively as CK2 discloses the possibility of using their scaffolds for the rational development of selective inhibitors of these kinases, with special reference to PIMs, DYRKs, HIPK2, PKD and ERK8.

1 January 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JBJan Balzarini
Jan Balzarini
BOBarbara Orzeszko-Krzesińska
Barbara Orzeszko-Krzesińska
JMJan Krzysztof Maurin
Jan Krzysztof Maurin
AOAndrzej Orzeszko
Andrzej Orzeszko

1 October 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Alessandra GianoncelliAlessandra Gianoncelli
Alessandra Gianoncelli
Giorgio CozzaGiorgio Cozza
Giorgio Cozza
AOAndrzej Orzeszko
Andrzej Orzeszko
FMFlavio Meggio
Flavio Meggio
ZKZygmunt Kazimierczuk
Zygmunt Kazimierczuk
LPLuigi Pinna
Luigi Pinna

18 January 2014 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
Giorgio CozzaGiorgio Cozza
Giorgio Cozza
CGCristina Girardi
Cristina Girardi
ARAlessandro Ranchio
Alessandro Ranchio
GLGraziano Lolli
Graziano Lolli
SSStefania Sarno
Stefania Sarno
LPLuigi Pinna
Luigi Pinna